Advertisement

Antifungal Medications in Neutropenia

  • Rod QuilitzEmail author
Chapter

Abstract

Over the last two decades, clinicians managing invasive fungal infections in neutropenic cancer patients have encountered many challenges – please see chapter on “Fungal Infections”. Fortunately we have also seen an expansion in our antifungal armamentarium during this time frame as well. This chapter will focus on the antifungal agents which are utilized for the prevention and treatment of invasive fungal infections in the neutropenic cancer patient. Specifically, we will discuss the polyene antifungal amphotericin B, the anti-metabolite flucytosine, select azole antifungals (fluconazole, voriconazole, posaconazole, isavuconazonium sulfate), and the echinocandins (caspofungin, micafungin, anidulafungin).

Keywords

Polyene Antifungals Amphotericin B deoxycholate Nystatin Flucytosine Azole antifungal Fluconazole Voriconazole Posaconazole Isavuconazonium sulfate Echinocandin Antifungals Caspofungin Micafungin 

References

  1. 1.
    National Center for Biotechnology Information. PubChem Compound Database; CID=71311649. https://pubchem.ncbi.nlm.nih.gov/compound/71311649. Accessed 20 Apr 2018.
  2. 2.
    Saravolatz LD, Ostrosky-Zeichner LO, Marr KA, Rex JH, Cohen SH. Amphotericin B: time for a new “Gold Standard”. Clin Infect Dis. 2003;37(3):415–25.CrossRefGoogle Scholar
  3. 3.
    Amphotericin B deoxycholate prescribing information. X-Gen Pharmaceuticals, Inc. Big Flats, New York. Revised December 2009.Google Scholar
  4. 4.
    Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(Suppl 1):7–10.CrossRefGoogle Scholar
  5. 5.
    Van Der Linden JWM, Warris A, Verweij PE. Aspergillus species intrinsically resistant to antifungal agents. Med Mycol. 2011;49(Suppl 1):S82–9.CrossRefGoogle Scholar
  6. 6.
    Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, et al. Trichosporin beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol. 1990;28(7):1616–22.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Sarma S, Upadhyay S. Current perspective on emergence, diagnosis, and drug resistance in Candida auris. Infect Drug Resist. 2017;10:155–65.CrossRefGoogle Scholar
  8. 8.
    Stempel JM, Hammond SP, Sutton DA, Weiser LM, Marty FM. Invasive fusariosis in the voriconazole era: single center 13-year experience. Open Forum Infect Dis. 2015;2(3):ofv099.  https://doi.org/10.1093/ofid/ofv099. eCollection 2015 SepCrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Patel R. Antifungal agents. Part 1. Amphotericin B preparation and flucytosine. Mayo Clinical Proceedings. 1998;73(12):1205–25.CrossRefGoogle Scholar
  10. 10.
    Eriksson U, Seifert B, Schaffner A. Comparsion of effects of amphotericin B deoxycholate infused over 4 or 24 hours. Br Med J. 2010;322:1–6.Google Scholar
  11. 11.
    Karimzadeh I, Farsaei S, Khalili H, Dashti-Khavidak S. Are salt loading and prolonging infusion period effective in prevention of amphotericin B induced nephrotoxicity? Expert Opin Drug Safety. 2012;11(6):969–83.CrossRefGoogle Scholar
  12. 12.
    Bearden T, Muncey LA. The effect of amiloride on amphotericin B-induced hypokalemia. J Antimicrob Chemother. 2001;48:109–11.CrossRefGoogle Scholar
  13. 13.
    Hamill RJ. Amphotericin B formulations: a comparative review of efficacy and toxicity. Drugs. 2013;73(9):919–34.CrossRefGoogle Scholar
  14. 14.
    Wingard JR, White MH, Anaissie E, Raffalli JR, Goodman J, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis. 2000;31:1155–63.CrossRefGoogle Scholar
  15. 15.
    Bowden R, Chandrasekar P, White MH, Pietrelli L, Gurwith M, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion verus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis. 2002;35(4):359–66.CrossRefGoogle Scholar
  16. 16.
    Roden MM, Nelson LD, Knudsen TA, Jarosinski PF, Starling JM, et al. Triad of acute infusion-related reactions associated with Liposomal Amphotericin B. Clin Infect Dis. 2003;36:1213–20.CrossRefGoogle Scholar
  17. 17.
    Pham P, Bartlett JG. Amphotericin B. Johns Hopkins ABX Guide. Accessed 4–20-18.Google Scholar
  18. 18.
    Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, et al. Liposomal amphotericin B as initial therapy for invasive mold infections: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44:1289–97.CrossRefGoogle Scholar
  19. 19.
    Gubbins PO, Amsden JR, McConnell SA, Anaissie EJ. Pharmacokinetics and Buccal Mucosal Concetrations of 15 mg/kg total dose of liposomal amphotericin B as single dose, weekly dose, or daily dose in peripheral stem cell transplant patients. Antimicrob Agents Chemother. 2009;53(9):3664–74.CrossRefGoogle Scholar
  20. 20.
    Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, et al. Safety of weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients. Int J Antimicrob Agents. 2008;31:135–41.CrossRefGoogle Scholar
  21. 21.
    Annino L, Chierichini A, Anaclerico B, Finolezzi E, Norata M, et al. Prospective phase II single-center study of the safety of a single very high dose of liposomal amphotericin B for antifungal prophylaxis in patients with acute myeloid leukemia. Antimicrob Agents Chemother. 2013;57(6):2596–602.CrossRefGoogle Scholar
  22. 22.
    Rijinders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduign JK, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia. Clin Infect Dis. 2008;46:1401–11.CrossRefGoogle Scholar
  23. 23.
    National Center for Biotechnology Information. PubChem Compound Database; CID= 6433272. https://pubchem.ncbi.nlm.nih.gov/compound/6433272. Accessed 27 Aug 2018.
  24. 24.
    Ng AW, Wasan KM, Lopez-Berestein G. Development of liposomal polyene antibiotics: an historical perspective. J Pharm Pharm Sci. 2003;6(1):67–83.PubMedGoogle Scholar
  25. 25.
    Offner F, Krcmery V, Boogaerts M, Doyen C, Engelhard D, et al. Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B. Antimicrob Agents Chemother. 2004;48(12):4808–12.CrossRefGoogle Scholar
  26. 26.
    Pam PA, Bartlett JG. Nystatin. Johns Hopkins ABX Guide. Accessed 8-27-18.Google Scholar
  27. 27.
    National Center for Biotechnology Information. PubChem Compound Database; CID=3366. https://pubchem.ncbi.nlm.nih.gov/compound/3366. Accessed 24 Apr 2018.
  28. 28.
    Ancobon (flucytosine) capsules prescribing information. Valeant Pharmaceuticals International. Costa Mesa, California. Revised May 2006.Google Scholar
  29. 29.
    Vermes A, Guchelaar H-J, Dankert J. Flucytosine: a review of its pharmacology, clinical indications, pharmacokinetics, toxicity, and drug interactions. J Antimicrob Chemother. 2000;46(2):171–9.CrossRefGoogle Scholar
  30. 30.
    Day JN, Chau TTH, Wolbers M, Mai PP, Dung NT, et al. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med. 2013;14:1291–302.CrossRefGoogle Scholar
  31. 31.
    Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr K, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1–e50.CrossRefGoogle Scholar
  32. 32.
    Patterson TG, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrectht R, et al. Practice guidelines for the diagnosis and management of aspergillus: 2016 update. Clin Infect Dis 2–16. 63(4):e1–e60.Google Scholar
  33. 33.
    Merry M, Boulware DR. Cryptococcal meningitis treatment strategies affected by the explosive cost of fluctyosine in the United States: a cost-effectiveness analysis. Clin Infect Dis. 2016;62(12):1564–8.CrossRefGoogle Scholar
  34. 34.
    Pham P, Bartlett JG. Flucytosine. Johns Hopkins ABX Guide. Accessed 4-24-18.Google Scholar
  35. 35.
    Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12(4):501–17.CrossRefGoogle Scholar
  36. 36.
    National Center for Biotechnology Information. PubChem Compound Database; CID=3365. https://pubchem.ncbi.nlm.nih.gov/compound/3365. Accessed 24 Apr 2018.
  37. 37.
    Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50:291–322.CrossRefGoogle Scholar
  38. 38.
    Zeuli JD, Wilson JW, Estes LL. Effect of combined fluroquinolone and azole use on QT prolongation in hematology patients 2013; 57(3): 1121–1127.Google Scholar
  39. 39.
    National Center for Biotechnology Information. PubChem Compound Database; CID=71616. https://pubchem.ncbi.nlm.nih.gov/compound/71616. Accessed 24 Apr 2018.
  40. 40.
    Pham P, Bartlett JG. Fluconazole. Johns Hopkins ABX Guide. Accessed 4-24-18.Google Scholar
  41. 41.
    Vfend (Voriconazole) prescribing information. Roerig, division of Pfizer. New York. Revised June 2010.Google Scholar
  42. 42.
    Pavie J, Lacroix C, Hermoso DG, Robin M, Ferry C, et al. Breakthrough disseminated aspergillus ustus infection in allogeneic hematopoietic stem cell transplant reccipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol. 2005;43(9):4902–4.CrossRefGoogle Scholar
  43. 43.
    Goldman C, Akiyama MJ, Torres J, Louie E, Meehan SA. Scedosporium aposperium and role of combination antifungal therapy and GM-CSF. Med Mycol Case Rep. 2016;11:40–3.CrossRefGoogle Scholar
  44. 44.
    Lewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2(4):348–55.CrossRefGoogle Scholar
  45. 45.
    Pham PA. Bartlett JG. Voriconazole. Johns Hopkins ABX Guide. Accessed 4-29-18.Google Scholar
  46. 46.
    Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patient with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46:201–11.CrossRefGoogle Scholar
  47. 47.
    Drinkwater DC, Davidson-Moncada J, Heckendorn E, Myers J, Whitman TJ. A patient with ulcerated nodules on his face. Clin Infect Dis. 2014;58:901–2.CrossRefGoogle Scholar
  48. 48.
    Thompson GR, Bays D, Cohen SH, Pappagianis D. Fluroride excess in coccidioidomycosis patients receiving long term antifungal therapy. Antimicrob Agents Chemother. 2012;56(1):563–4.CrossRefGoogle Scholar
  49. 49.
    Williams D. The effect of enteral nutrition supplements on serum voriconazole levels. J Oncol Pharm Pract. 2011;18(1):128–31.CrossRefGoogle Scholar
  50. 50.
    Obeng O, Egelund EF, Asiltan A, Peloquin CA, Johnson JA. CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole.Google Scholar
  51. 51.
    Dickmeyer NJ, Kiel PJ. Dosing voriconazole in an obese patient. Clin Infect Dis. 2011;53:745.CrossRefGoogle Scholar
  52. 52.
    Smith J, Safdar N, Knansinski V, Simmons W, Bhavnani SM, Ambrose PG, Andes D. Antimicrob Agents Chemother. 2006;50:1570–22.CrossRefGoogle Scholar
  53. 53.
    Turner RB, Martello JL, Malhorta A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole. Int J Antimicrob Agents. 2015;46(4):362–6.CrossRefGoogle Scholar
  54. 54.
    National Center for Biotechnology Information. PubChem Compound Database; CID=468595. https://pubchem.ncbi.nlm.nih.gov/compound/468595. Accessed 29 Apr 2018.
  55. 55.
    Nagappan V, Deresinski S. Posaconazole: A broad-spectrum triazole antifungal agent. Clin Infect Dis. 2007;45:1610–6.CrossRefGoogle Scholar
  56. 56.
    Noxafil (posaconazole) prescribing information. Merck. Whitehouse Station. Revised 2014.Google Scholar
  57. 57.
    Walish TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, et al. Treatment in invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy. Clin Infect Dis. 2007;44:2–12.CrossRefGoogle Scholar
  58. 58.
    Greenberg RN, Mullane K, van Burik J-AH, Raad I, Abzug MJ, et al. Posconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother. 2006;50(1):126–33.CrossRefGoogle Scholar
  59. 59.
    Pam PA, Bartlett JG. Posconazole. Johns Hopkins ABX Guide. Accessed 4-29-18.Google Scholar
  60. 60.
    Green MR, Woolery JE. Optimising absorption of posaconazole. Mycoses. 2011;54:e775–9.CrossRefGoogle Scholar
  61. 61.
    National Center for Biotechnology Information. PubChem Compound Database; CID=72196309. https://pubchem.ncbi.nlm.nih.gov/compound/72196309. Accessed 3 May 2018.
  62. 62.
    National Center for Biotechnology Information. PubChem Compound Database; CID=6918485. https://pubchem.ncbi.nlm.nih.gov/compound/6918485. Accessed 3 May 2018.
  63. 63.
    Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect Dis. 2015;61(10):1558–65.CrossRefGoogle Scholar
  64. 64.
    Cresemba (isavuconazonium sulfate) prescribing information. Astellas Pharma Inc. Northbrook. Revised June 2015.Google Scholar
  65. 65.
    Cornely OA, Bohme A, Schmitt-Hoffman A, Ulmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia. Antimicrob Agents Chemother. 2015;59:2078–85.CrossRefGoogle Scholar
  66. 66.
    Viljoen J, Schmitt-Hoffman A, Ghannoum M. A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared to fluconazole in patients with uncomplicated esophageal candidiasis. Antimicro Agents Chemother. 2015;59(3):1671–9.CrossRefGoogle Scholar
  67. 67.
    Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE). Lancet. 2016;387(10020):760–9.  https://doi.org/10.1016/S0140-6736(15)01159-9.. Epub 2015 Dec 10CrossRefPubMedGoogle Scholar
  68. 68.
    Pettit NN, Carver PL. Isavuconazole: a new option for the management of invasive fungal infections. Ann Pharmacother. 2015;49(7):825–42.CrossRefGoogle Scholar
  69. 69.
    National Center for Biotechnology Information. PubChem Compound Database; CID=66577041. https://pubchem.ncbi.nlm.nih.gov/compound/66577041. Accessed 3 May 2018.
  70. 70.
    National Center for Biotechnology Information. PubChem Compound Database; CID=477468. https://pubchem.ncbi.nlm.nih.gov/compound/477468. Accessed 3 May 2018.
  71. 71.
    National Center for Biotechnology Information. PubChem Compound Database; CID=166548. https://pubchem.ncbi.nlm.nih.gov/compound/166548. Accessed 3 May 2018.
  72. 72.
    Cancidas (caspofungin acetate) prescribing information. Merck and Company, Inc. Whitehouse Station. Revised Mar 2018.Google Scholar
  73. 73.
    Mycamine (micafungin) prescribing information. Astellas Pharma US, Inc. Northbrook. Revised Aug 2016.Google Scholar
  74. 74.
    Eraxis (anidulafungin) prescribing information. Pfizer. New York. Original prescribing information on February 16, 2006.Google Scholar
  75. 75.
    Eraxis (anidulafungin) prescribing information. Pfizer. New York. Revised January 2018.Google Scholar
  76. 76.
    Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;17(1):11–41.CrossRefGoogle Scholar
  77. 77.
    Perlin DS. Echinocandin resistance in Candida. Clin Infect Dis. 2015;61(Suppl 6):S612–7.CrossRefGoogle Scholar
  78. 78.
    Marr KA, Sclamm HT, Herbrect R, Rottinghaus ST, Bow EJ, et al. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Ann Intern Med. 2016;162(2):81–9.CrossRefGoogle Scholar
  79. 79.
    Wang J-L, Chang C-H, Young-Xu Y, Chan KA. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother. 2018;62:2409–19.Google Scholar
  80. 80.
    Koch C, Uhle F, Wolff M, Arens C, Schulte A, Li L, et al. Cardiac effects of echinocandins after central venous administration in adult rats. Antimicrob Agents Chemother. 2018;62(5):1612–9.Google Scholar
  81. 81.
    Nishimoto M, Koh H, Tokuwame A, Makuuchi Y, Kuono M, et al. Drug interactions and safety profiles with concomitant use of casofungin and calcineurin inhibitors in allogeneic haemtolopoietic cell transplantation. Br J Clin Pharmacol. 2017;83(9):2000–7.CrossRefGoogle Scholar
  82. 82.
    Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles T, et al. A multi-center double-blind trial of high-dose caspofungin treatment regimen versus standard caspofungin treatment regimen for adjust patients with invasive candidiasis. Clin Infect Dis. 2009;48:1676–84.CrossRefGoogle Scholar
  83. 83.
    Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, et al. Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: a randomized study. J Infect 2018; pii: S0163-4453(18)30132-4. doi:  https://doi.org/10.1016/j.jinf.2018.03.015. [Epub ahead of print].CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Infectious Diseases and Antimicrobial StewardshipMoffitt Cancer CenterTampaUSA

Personalised recommendations